TWI564305B - 治療性抗體 - Google Patents

治療性抗體 Download PDF

Info

Publication number
TWI564305B
TWI564305B TW101120198A TW101120198A TWI564305B TW I564305 B TWI564305 B TW I564305B TW 101120198 A TW101120198 A TW 101120198A TW 101120198 A TW101120198 A TW 101120198A TW I564305 B TWI564305 B TW I564305B
Authority
TW
Taiwan
Prior art keywords
antibody
seq
sequence
human
antibodies
Prior art date
Application number
TW101120198A
Other languages
English (en)
Chinese (zh)
Other versions
TW201311724A (zh
Inventor
史戴方 蒼
路易斯 海傑瑞德 卓森
安克 瓊 漢森
克里斯堤恩 克潔賈德
斯倫 朗德
Original Assignee
諾佛 儂迪克股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 諾佛 儂迪克股份有限公司 filed Critical 諾佛 儂迪克股份有限公司
Publication of TW201311724A publication Critical patent/TW201311724A/zh
Application granted granted Critical
Publication of TWI564305B publication Critical patent/TWI564305B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
TW101120198A 2011-06-06 2012-06-06 治療性抗體 TWI564305B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11168787 2011-06-06
US201161505137P 2011-07-07 2011-07-07
EP12159172 2012-03-13

Publications (2)

Publication Number Publication Date
TW201311724A TW201311724A (zh) 2013-03-16
TWI564305B true TWI564305B (zh) 2017-01-01

Family

ID=47295509

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101120198A TWI564305B (zh) 2011-06-06 2012-06-06 治療性抗體

Country Status (16)

Country Link
US (7) US8613926B2 (enExample)
EP (3) EP2718322B1 (enExample)
JP (2) JP6141834B2 (enExample)
KR (1) KR101978757B1 (enExample)
CN (1) CN103596982B (enExample)
AU (1) AU2012266487B2 (enExample)
BR (1) BR112013031198B1 (enExample)
CA (1) CA2838497C (enExample)
DK (3) DK2718322T3 (enExample)
ES (2) ES2929575T3 (enExample)
IL (1) IL229254A (enExample)
PL (2) PL2718322T3 (enExample)
PT (1) PT3424953T (enExample)
RU (1) RU2616881C2 (enExample)
TW (1) TWI564305B (enExample)
WO (1) WO2012168199A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2718322T3 (pl) * 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
US20160333108A1 (en) * 2014-01-13 2016-11-17 Stephen J. Forman CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
US20170107294A1 (en) * 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
MX388181B (es) 2014-07-22 2025-03-19 Cb Therapeutics Inc Anticuerpos anti-pd-1.
JP6909153B2 (ja) 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド 抗ｐｄ−ｌ１抗体
US20170328898A1 (en) * 2014-10-31 2017-11-16 Cell Trend GmbH Diagnosis of an autoimmune disease using detection of antibodies directed against c5a-receptor
CN108779174B (zh) * 2015-11-04 2022-11-29 希望之城公司 靶向her2的嵌合抗原受体
JP2019509014A (ja) * 2015-11-23 2019-04-04 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｃｄ３９血管アイソフォームターゲティング剤
DK3380522T5 (da) 2015-11-25 2024-09-30 Visterra Inc Antistofmolekyler til april og anvendelser deraf
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
RU2021129189A (ru) 2016-01-22 2021-11-15 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
MY201852A (en) 2016-06-14 2024-03-20 Merck Sharp & Dohme Llc Anti-coagulation factor xi antibodies
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
EP3978523A1 (en) 2017-04-03 2022-04-06 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
US20200299400A1 (en) * 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
WO2019092148A1 (en) * 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
AU2019289646B2 (en) 2018-06-18 2025-10-23 Innate Pharma Compositions and methods for treating cancer
EA202190647A1 (ru) 2018-09-17 2021-09-09 Абкуро, Инк. Антитела к klrg1
CA3121699A1 (en) * 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
EP3938393A1 (en) 2019-03-14 2022-01-19 MorphoSys AG Antibodies targeting c5ar
EP4071167A4 (en) * 2019-12-03 2024-03-06 Shanghai Jiao Tong University School of Medicine ANTIBODIES FC REGION WITH INCREASED FCGRIB AFFINITY
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
US20230340140A1 (en) 2020-08-12 2023-10-26 Innate Pharma Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
WO2022090556A1 (en) 2020-11-02 2022-05-05 Hummingbird Bioscience Pte. Ltd. Bcma/taci antigen-binding molecules
CN120309734A (zh) 2021-01-13 2025-07-15 威特拉公司 人源化补体5a受体1抗体和其使用方法
WO2022189667A1 (en) 2021-03-12 2022-09-15 Genmab A/S Non-activating antibody variants
JP2024535053A (ja) 2021-09-16 2024-09-26 ハミングバード・バイオサイエンス・プライベート・リミテッド Ｖｉｓｔａ抗原結合性分子を使用する、がんの処置および防止
WO2023046979A1 (en) 2021-09-27 2023-03-30 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
AR127298A1 (es) * 2021-10-08 2024-01-10 Genmab As Anticuerpos que se unen a cd30 y cd3
EP4450081A4 (en) * 2021-12-16 2025-05-07 Shanghai Bao Pharmaceuticals Co., Ltd. Anti-immunoglobulin-degrading enzyme-fermented FC variant
TW202409280A (zh) 2022-07-08 2024-03-01 新加坡科技研究局 Cnx抗原結合分子
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
US20260098093A1 (en) 2022-09-22 2026-04-09 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
US20240238439A1 (en) 2023-01-03 2024-07-18 Hummingbird Bioscience Pte. Ltd. Her3-binding antibody-drug conjugate
CN121002069A (zh) 2023-01-06 2025-11-21 泰温治疗私人有限公司 抗原结合分子
EP4646439A1 (en) 2023-01-06 2025-11-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
WO2025125495A1 (en) 2023-12-13 2025-06-19 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
WO2025133322A1 (en) 2023-12-22 2025-06-26 Agency For Science, Technology And Research Cnx antigen-binding molecules
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
WO2025257350A1 (en) 2024-06-13 2025-12-18 Singapore Health Services Pte Ltd Pai-1 antigen-binding molecules
EP4670793A1 (en) 2024-06-24 2025-12-31 Montis Biosciences BV C1Q ANTIGEN BINDING MOLECULES
WO2026033139A1 (en) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
WO2026033132A1 (en) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
WO2026033134A1 (en) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
WO2026062072A1 (en) 2024-09-18 2026-03-26 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
WO2026063874A1 (en) 2024-09-20 2026-03-26 Hummingbird Bioscience Pte. Ltd. B7-h3 antigen-binding molecules
WO2026062200A1 (en) 2024-09-20 2026-03-26 Hummingbird Bioscience Pte. Ltd. B7-h3 antigen-binding molecules
WO2026062240A1 (en) 2024-09-20 2026-03-26 Albatroz Therapeutics Pte. Ltd. Inhibition of calnexin for the treatment of inflammatory bowel disease
WO2026068570A1 (en) 2024-09-25 2026-04-02 Singapore Health Services Pte. Ltd. Lrg1 antigen-binding molecules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506237A (zh) * 2006-08-22 2009-08-12 G2炎症私人有限公司 具有改进性能的抗-C5aR抗体

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JPH02262599A (ja) 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5861272A (en) 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
US20010036650A1 (en) 1994-08-16 2001-11-01 Human Genome Sciences, Inc. C5a receptor
JPH08109200A (ja) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd 抗Ｃ５ａレセプター抗体、その製造法および用途
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JPH11507513A (ja) 1995-06-05 1999-07-06 インサイト・ファーマスーティカルズ・インコーポレイテッド Ｃ５ａ様７膜貫通受容体
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
WO1998033908A1 (en) 1997-01-31 1998-08-06 Incyte Pharmaceuticals, Inc. Human c5a-like receptor
AU7266698A (en) 1997-04-30 1998-11-24 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
WO2002038767A2 (en) 2000-11-07 2002-05-16 Genetics Institute, Llc. G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
DK1409646T3 (da) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TWI327597B (en) * 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
CA2457461C (en) 2001-08-17 2013-12-24 Tanox, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
NZ534399A (en) 2002-01-25 2008-08-29 G2 Therapies Ltd Monoclonal antibodies against extracellular loops of C5aR
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2003300776A1 (en) 2002-09-09 2004-05-25 Omeros Corporation G protein coupled receptors and uses thereof
AU2002952086A0 (en) 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
ATE472556T1 (de) * 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2004082568A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
EP1586583A3 (en) 2004-04-16 2005-11-16 Alligator Bioscience AB (publ) Compounds that block C5a complement receptor and their use in therapy
EP3312196B1 (en) * 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
WO2007055374A1 (ja) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
WO2008022391A1 (en) 2006-08-22 2008-02-28 G2 Inflammation Pty Ltd Method for producing antibodies
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
AU2008314697B2 (en) * 2007-10-22 2013-08-29 Merck Serono S.A. Single IFN-beta fused to a mutated lgG Fc fragment
CN104193824A (zh) 2008-02-20 2014-12-10 G2炎症私人有限公司 人源化抗-C5aR抗体
US9040507B2 (en) 2008-06-02 2015-05-26 Novelmed Therapeutics, Inc. Method for treating inflammatory conditions
US20090324585A1 (en) 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
WO2010000864A1 (en) 2008-07-04 2010-01-07 Novo Nordisk A/S Method for producing monoclonal antibodies
SMT202200074T1 (it) 2008-12-22 2022-03-21 Chemocentryx Inc Antagonisti di c5ar
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
US9260518B2 (en) * 2010-06-30 2016-02-16 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
US20130183280A1 (en) * 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
CA2822288A1 (en) * 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
DK2994488T3 (da) 2013-05-08 2022-10-03 Novo Nordisk As Anvendelse af c5ar-antagonister

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506237A (zh) * 2006-08-22 2009-08-12 G2炎症私人有限公司 具有改进性能的抗-C5aR抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Strohl, W.," Optimization of Fc-Mediated Effector Functions of Monoclonal Antibodies", Curr. Opin. Biotechnol., 2009, Vol.20, Issue 6, P.685-691. *

Also Published As

Publication number Publication date
RU2616881C2 (ru) 2017-04-18
JP6141834B2 (ja) 2017-06-07
DK3424953T3 (en) 2020-11-02
RU2013155029A (ru) 2015-07-20
CN103596982B (zh) 2016-11-02
BR112013031198B1 (pt) 2020-10-20
PT3424953T (pt) 2020-11-03
US10323097B2 (en) 2019-06-18
KR101978757B1 (ko) 2019-05-15
US20210238300A1 (en) 2021-08-05
KR20140036261A (ko) 2014-03-25
EP2718322B1 (en) 2018-08-08
JP2017081941A (ja) 2017-05-18
DK3798230T3 (en) 2022-10-31
IL229254A (en) 2017-09-28
WO2012168199A1 (en) 2012-12-13
TW201311724A (zh) 2013-03-16
CN103596982A (zh) 2014-02-19
AU2012266487B2 (en) 2016-12-08
US8846045B2 (en) 2014-09-30
PL3424953T3 (pl) 2021-01-25
US20240218076A1 (en) 2024-07-04
ES2929575T3 (es) 2022-11-30
CA2838497C (en) 2023-02-28
BR112013031198A2 (pt) 2016-11-29
EP3424953A1 (en) 2019-01-09
US20130004514A1 (en) 2013-01-03
BR112013031198A8 (pt) 2018-01-16
US20150044231A1 (en) 2015-02-12
JP6416177B2 (ja) 2018-10-31
EP3424953B1 (en) 2020-08-05
CA2838497A1 (en) 2012-12-13
US20200017599A1 (en) 2020-01-16
US20170073421A1 (en) 2017-03-16
AU2012266487A1 (en) 2013-11-21
JP2014523408A (ja) 2014-09-11
EP3798230B1 (en) 2022-08-03
US10882916B2 (en) 2021-01-05
US8613926B2 (en) 2013-12-24
IL229254A0 (en) 2014-01-30
EP3798230A1 (en) 2021-03-31
ES2693647T3 (es) 2018-12-13
EP2718322A1 (en) 2014-04-16
PL2718322T3 (pl) 2019-07-31
US20130295116A1 (en) 2013-11-07
DK2718322T3 (en) 2018-12-03

Similar Documents

Publication Publication Date Title
US20240218076A1 (en) Therapeutic antibodies
US11680097B2 (en) Antibodies against canine PD-1
US11993658B2 (en) Anti-BCMA antibodies and treatment methods
WO2019087094A1 (en) Anti-cd40 antibodies for use in treatment of sjögren's syndrome
CN116981477A (zh) 抗masp2抗体、其抗原结合片段及医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CA3239307A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha 1
WO2022022662A1 (zh) Cd47抗体及其应用
ES2831303T3 (es) Anticuerpos terapéuticos
WO2023283211A2 (en) Cd21 antibodies and uses thereof
MX2013013911A (es) Anticuerpos terapeuticos.